Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to explain why he's selling Pfizer here.

(Reuters) -US drugmakers Bristol Myers and Pfizer said on Thursday that they will make their blood thinner, Eliquis, ...

The reduced rate will still be almost 10 times the average monthly out-of-pocket costs paid by commercially insured patients.

Taking a page from Eli Lilly and Novo Nordisk, who have launched online programs to sell their diabetes and obesity drugs ...

Bristol Myers and Pfizer will sell Eliquis directly to U.S. patients at a discounted rate with transparent pricing and ...

A Harvard Business School Healthcare Alumni Association Q&A with Dr. Henry A. McKinnell, former Chairman and CEO of Pfizer.

A clip of Albert Bourla, in which he appears to refer to a goal of reducing the number of people in the world by 50%, has ...

Pharmaceutical giants introduce an insurance-free pathway for top anticoagulant Eliquis, following similar direct-to-patient models from Eli Lilly and Novo Nordisk.

One of the best known communications executives in corporate America, Susman worked at Pfizer for nearly two decades after ...

Kenvue (KVUE), the company behind Tylenol and Neutrogena, announced that Thibaut Mongon had left the company, naming Kirk ...

Following in the footsteps of other pharmaceutical companies, Bristol Myers Squibb and Pfizer are offering Eliquis for cash-paying patients at a discount of 40% off the list price.